Safety updates from EMA's CHMP

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1360, 2011-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CHMP safety updates for Avastin and Thelin

By  

Reactions Weekly, Vol. 1, Iss. 1300, 2010-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

The EMA's CHMP is recommending updates to Summary of Product Characteristics (SmPC) of agomelatine [Thymanax, Valdoxan]

By  

Reactions Weekly, Vol. 1, Iss. 1421, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Safety updates from the TGA

By  

Reactions Weekly, Vol. 1, Iss. 1364, 2011-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

CHMP opinions on safety variations

By  

Reactions Weekly, Vol. 1, Iss. 1391, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Refusal of the marketing authorisation for Sumatriptan Galpharm has been confirmed by the EMA's CHMP.

By  

Reactions Weekly, Vol. 1, Iss. 1380, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite